JayAdamLiebermanMD

Asthma & Allergic Conditions

Assistant Professor, Pediatrics, University of Tennessee Health Science Center College of Medicine

Dr. Lieberman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
51 N Dunlap St
Ste 400
Memphis, TN 38105
Phone+1 901-287-7337

Fax+1 901-266-6488

Dr. Jay Lieberman is an allergist/immunologist in Memphis, TN and is affiliated with multiple hospitals in the area, including Le Bonheur Children's Hospital and Methodist Healthcare Memphis Hospitals. He received his medical degree from University of Tennessee College of Medicine and has been in practice 11 years. He specializes in asthma & allergic conditions.

Icahn School of Medicine at Mount SinaiFellowship, Allergy and Immunology, 2009 - 2011
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
University of Tennessee Health Science Center College of MedicineClass of 2006

PubMed

Perceptions, realities, and alternatives in rescue epinephrine.
Matthew Greenhawt, John Oppenheimer, Jay Lieberman, Marcus S Shaker, Jonathan M Spergel
Annals of Allergy, Asthma & Immunology. 2024-12-01
Pharmacokinetic and Pharmacodynamic Profile of Epinephrine Nasal Spray Versus Intramuscular Epinephrine Autoinjector in Healthy Adults.
Matthew Greenhawt, Jay Lieberman, Michael Blaiss, David I Bernstein, John Oppenheimer
The Journal of Allergy and Clinical Immunology. in Practice. 2024-12-01
Corrigendum to <'A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the America...
Jay A Lieberman, Derek K Chu, Tasnuva Ahmed, Timothy E Dribin, Elissa M Abrams
Annals of Allergy, Asthma & Immunology. 2024-11-02

Anaphylm Sublingual Film May Resolve Symptoms of Severe Allergic Reactions Including Anaphylaxis: OAS Challenge StudyOctober 24th, 2024
Leadiant Biosciences Is Conducting the Registry Study of Revcovi® Treatment in Patients with ADA-SCIDFebruary 11th, 2020
FDA Signs off on New Peanut Allergy TherapyFebruary 3rd, 2020
Join now to see all